Emyria Ltd · ASX:EMD
Emyria — Euroz Hartleys 2025 Healthcare Forum
24 slides from Emyria's conference presentation, Feb 4, 2025
Slide 1: Responding to Australia's Mental Health Crisis
For personal use only ASX : EMD RESPONDING TO AUSTRALIA’S MENTAL HEALTH CRISIS Advanced therapies. Compassionate care. 04 February 2025 Euroz Healthcare Forum
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. T
Slide 3: The Growing Global Mental Health Challenge
THE GROWING GLOBAL MENTAL HEALTH CHALLENGE For personal use only Half of the global population will experience mental illness. 1 Mental health disorders could cost the world $16 trillion by 2030. 2 SOURCES: 1. https://hms.harvard.edu/news/half-worlds-population-will-experience-mental-health-disorder
Slide 4: Australian Mental Health: Annual Expenditure Comparison
AUSTRALIAN MENTAL HEALTH | ANNUAL EXPENDITURE COMPARISON Cancer 1 Mental Health 2 For personal use only $12.2B $10.1B Increasing amounts being spent on mental health… SOURCES: 1. https://www.aihw.gov.au/reports/cancer/health-system-expenditure-cancer-other-neoplasms/summary Emyria 2025 4 2. https://
Slide 5: Australian Mental Health: Now Our #1, Rising, Chronic Health Problem
AUSTRALIAN MENTAL HEALTH | NOW OUR #1, RISING, CHRONIC HEALTH PROBLEM For personal use only …yet, prevalence of mental health is increasing 6 Emyria 2025 5
Slide 6: Australian Mental Health: Workforce Under Pressure
AUSTRALIAN MENTAL HEALTH | WORKFORCE UNDER PRESSURE For personal use only 1 2 3 4 5 SOURCES: 1. Financial Review, 25 October 2024 4. The West Australian, 05 February 2024 Emyria 2025 6 2. Channel 9 News 23 January 2025 5. UQ News, 22 November 2024 3. Human Resources Director, 23 November 2024 6. Hou
Slide 7: Australia's Unique Opportunity: An Access Pathway for Two New Treatments
AUSTRALIA’S UNIQUE OPPORTUNITY | AN ACCESS PATHWAY FOR TWO NEW TREATMENTS For personal use only MDMA Australia is the ONLY jurisdiction in the world to reschedule two promising treatments 1 Psilocybin Emyria 2025 7
Slide 8: Psychedelics to Tackle Treatment Resistant PTSD and Depression
PSYCHEDELICS TO TACKLE TREATMENT RESISTANT PTSD and DEPRESSION MDMA-Assisted Therapy for Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder Treatment-Resistant Depression For personal use only PTSD is a chronic, debilitating condition that TR-D is major depression that does not improve c
Slide 9: Psychedelic-Assisted Therapy: A New Treatment Paradigm
PSYCHEDELIC-ASSISTED THERAPY | A NEW TREATMENT PARADIGM For personal use only Potent, psychoactive Intensive and medications supportive psychotherapy Specialists Therapists Emyria 2025 9
Slide 10: Case Study: Kate, From Workers Comp to Back-to-Work
CASE STUDY | KATE | FROM WORKERS COMP TO BACK-TO-WORK 5 years MDMA-AT commenced For personal use only Kate’s story: First responder ● PTSD due to cumulative workplace traumas ● Myriad of therapies: EMDR, in-vivo, ACT, CBT, mindfulness, somatic exercises, TMS, imagery rescripting, nightmare PCL-5 SCO
Slide 11: Emyria's PTSD Program: Symptom Improvement Post-Treatment
EMYRIA’S PTSD PROGRAM | 3 MONTHS POST-TREATMENT | SYMPTOM IMPROVEMENT Average PCL-5 1 Scores by Visit (up to 3 months follow-up) For personal use only Typical last treatment Patients continue to improve after active treatment has ended. End of 1st End of 2nd End of 3rd 3 months after Baseline Cycle
Slide 12: Emyria's PTSD Program: Quality of Life Improvement
EMYRIA’S PTSD PROGRAM | 3 MONTHS POST-TREATMENT | Quality of Life IMPROVEMENT Average ReQoL 1 Scores by Visit (up to 3 months follow-up) For personal use only Typical last treatment Patients continue to improve after active treatment has ended. End of 1st End of 2nd End of 3rd 3 months after Baselin
Slide 13: Why Can't Everyone Do This? The Significant Barriers to Entry
WHY CAN’T EVERYONE DO THIS? THE SIGNIFICANT BARRIERS TO ENTRY! For personal use only ✓ ✓ TGA Approved Secure, Authorised pharmaceutical-grade Prescribers medication supply Emyria 2025 13
Slide 14: World-Class Facilities and a Skilled Team of Clinicians
WORLD-CLASS FACILITIES AND A SKILLED TEAM OF CLINICIANS For personal use only Emyria’s team of over 20 trained clinicians comprise: - Specialist psychiatrists, - psychologists, - mental health - nurses, counsellors, - social workers and; - occupational therapists Figure 1: Emyria 2025 14 12 of Emyri
Slide 15: Lifetime Prevalence of Serious Mental Illness in Australia
LIFETIME PREVALENCE OF SERIOUS MENTAL ILLNESS IN AUSTRALIA (million persons) ANXIETY DISORDERS AFFECTIVE DISORDERS For personal use only Generalised Panic PTSD = 2.1 Anxiety Depression = 2.3 Disorder = 1.2 Disorder = 1.6 Bipolar Dysthymia = Obsessive Compulsive Affective 0.5 Disorder = 0.8 Disorder
Slide 16: Addressable Patient Population, Today
ADDRESSABLE PATIENT POPULATION, TODAY ANXIETY DISORDERS AFFECTIVE DISORDERS For personal use only Avg treatment costs ~500,000 $20k-$30k / Eligible for pt PA-AT ~800,000 (show treatment resistance and meet Eligible for Total clinical criteria 2) MDMA-AT addressable market ~ (show treatment $36B resi
Slide 17: Growth Opportunity to Tackle Additional Unmet Needs
GROWTH OPPORTUNITY TO TACKLE ADDITIONAL UNMET NEEDS ANXIETY DISORDERS AFFECTIVE DISORDERS For personal use only Emyria uniquely poised to lead the advancement of P-AT to additional unmet needs in Australia and globally Psilocybin-AT MDMA-AT SOURCES: 1. Australian Bureau of Statistics, accessed 31 Ja
Slide 18: Emyria's Growth Strategy
EMYRIA’S GROWTH STRATEGY For personal use only Establish world-class, Expansion to be supported Leverage Emyria’s dedicated treatment by provider agreements proprietary Real-World centres, specialising in new with major private and Data to create better care psychiatric treatments 1 government funde
Slide 19: Emyria Investor Opportunity
EMYRIA (ASX:EMD) | INVESTOR OPPORTUNITY The only ASX-listed entity integrating direct care in psychedelic-assisted therapy For personal use only MAJOR UNMET A HARD-TO-COPY AN INCREDIBLE CLEAR GROWTH STRONG IP NEEDS - MENTAL TREATMENT THAT TEAM STRATEGY BACKED HEALTH WORKS BY MAJOR HEALTH PAYERS Emyr
Slide 20: Contact Information
CONTACT INFORMATION For personal use only Greg Hutchinson ghutchinson@emyria.com Michael Winlo mwinlo@emyria.com Investor / Media Inquiries investors@emyria.com Visit Our Investor Hub
Slide 21: Psychedelic-Assisted Therapy: Investment Interest Is Returning
PSYCHEDELIC-ASSISTED THERAPY | INVESTMENT INTEREST IS RETURNING Investor confidence in psychedelics is returning, driven by shifting political landscapes in the US that may signal broader acceptance and support for these treatments. For personal use only Most Attractive Investment Areas Q3’24 2 1 Sou
Slide 22: Corporate Overview
CORPORATE OVERVIEW SUBSTANTIAL SHAREHOLDERS For personal use only Shareholder % #1 Holder: Greg Hutchinson, Chairman 7.2% 1 Top 50 65.9% ASX: EMD TRADING INFORMATION Last Traded Share Price A$0.035 12-Month low / high A$0.026 / 0.076 Shares Outstanding 455,471,286 Market Capitalisation 2 A$15.6M Las
Slide 23: Emyria Leadership
EMYRIA LEADERSHIP | SIGNIFICANT CLINICAL SERVICES AND INNOVATION EXPERTISE For personal use only Greg Hutchinson Dr Michael Winlo Dr Karen Smith Dr Mohit Kaushal Prof Sir John Tooke Executive Chairman Executive Director Non-Executive Director Non-Executive Director Non-Executive Director ● Biopharma
Slide 24: Epidemiology of PTSD and Tr-Depression in Australia
EPIDEMIOLOGY OF PTSD and Tr-Depression in Australia 1 For personal use only Adults % with Adults % with Adult PTSD % with Adult PTSD aged 18-80 condition with chronic cases that disqualifying cases eligible (millions) 1 condition and are chronic condition 3 for MDMA-AT severe or severe PTSD 20.7 7-1